

# Global Targeted Drugs for Neurodegenerative Diseases Market Growth (Status and Outlook) 2024-2030

<https://marketpublishers.com/r/G88F05573551EN.html>

Date: November 2024

Pages: 135

Price: US\$ 3,660.00 (Single User License)

ID: G88F05573551EN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Targeted Drugs for Neurodegenerative Diseases market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the "Targeted Drugs for Neurodegenerative Diseases Industry Forecast" looks at past sales and reviews total world Targeted Drugs for Neurodegenerative Diseases sales in 2022, providing a comprehensive analysis by region and market sector of projected Targeted Drugs for Neurodegenerative Diseases sales for 2023 through 2029. With Targeted Drugs for Neurodegenerative Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Targeted Drugs for Neurodegenerative Diseases industry.

This Insight Report provides a comprehensive analysis of the global Targeted Drugs for Neurodegenerative Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Targeted Drugs for Neurodegenerative Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Targeted Drugs for Neurodegenerative Diseases market.

This Insight Report evaluates the key market trends, drivers, and affecting factors

shaping the global outlook for Targeted Drugs for Neurodegenerative Diseases and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Drugs for Neurodegenerative Diseases.

United States market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Targeted Drugs for Neurodegenerative Diseases is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Targeted Drugs for Neurodegenerative Diseases players cover Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Drugs for Neurodegenerative Diseases market by product type, application, key players and key regions and countries.

Segmentation by Type:

Injection

Oral

Segmentation by Application:

Parkinson's Disease (PD)

Alzheimer's Disease (AD)

Huntington's Disease (HD)

Tardive Dyskinesia (TD)

Multiple Sclerosis (MS)

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

#### Segmentation by Type:

Injection

Oral

#### Segmentation by Application:

Parkinson's Disease (PD)

Alzheimer's Disease (AD)

Huntington's Disease (HD)

Tardive Dyskinesia (TD)

Multiple Sclerosis (MS)

This report also splits the market by region:

#### Americas

United States

Canada

Mexico

Brazil

#### APAC

China

Japan

Korea

Southeast Asia

India

Australia

#### Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Acadia Pharmaceuticals Inc.

Kyowa Kirin

Supernus Pharmaceuticals

UCB

Sumitomo Pharma

Biogen

Eisai Inc.

Eli Lilly

Green Valley

NOVARTIS

Bristol-Myers Squibb

Janssen

Sanofi

Roche

Neurocrine

Lundbeck

Teva

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size 2019-2030
  - 2.1.2 Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Region (2019 VS 2023 VS 2030)
  - 2.1.3 World Current & Future Analysis for Targeted Drugs for Neurodegenerative Diseases by Country/Region, 2019, 2023 & 2030
- 2.2 Targeted Drugs for Neurodegenerative Diseases Segment by Type
  - 2.2.1 Injection
  - 2.2.2 Oral
- 2.3 Targeted Drugs for Neurodegenerative Diseases Market Size by Type
  - 2.3.1 Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Type (2019 VS 2023 VS 2030)
  - 2.3.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2019-2024)
- 2.4 Targeted Drugs for Neurodegenerative Diseases Segment by Application
  - 2.4.1 Parkinson's Disease (PD)
  - 2.4.2 Alzheimer's Disease (AD)
  - 2.4.3 Huntington's Disease (HD)
  - 2.4.4 Tardive Dyskinesia (TD)
  - 2.4.5 Multiple Sclerosis (MS)
- 2.5 Targeted Drugs for Neurodegenerative Diseases Market Size by Application
  - 2.5.1 Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Application (2019 VS 2023 VS 2030)
  - 2.5.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size Market



Share by Application (2019-2024)

### **3 TARGETED DRUGS FOR NEURODEGENERATIVE DISEASES MARKET SIZE BY PLAYER**

3.1 Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Player

3.1.1 Global Targeted Drugs for Neurodegenerative Diseases Revenue by Player (2019-2024)

3.1.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Player (2019-2024)

3.2 Global Targeted Drugs for Neurodegenerative Diseases Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

### **4 TARGETED DRUGS FOR NEURODEGENERATIVE DISEASES BY REGION**

4.1 Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2019-2024)

4.2 Global Targeted Drugs for Neurodegenerative Diseases Annual Revenue by Country/Region (2019-2024)

4.3 Americas Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2019-2024)

4.4 APAC Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2019-2024)

4.5 Europe Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2019-2024)

4.6 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth (2019-2024)

### **5 AMERICAS**

5.1 Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024)

5.2 Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Type

(2019-2024)

5.3 Americas Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2019-2024)

6.2 APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2019-2024)

6.3 APAC Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

## **7 EUROPE**

7.1 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024)

7.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2019-2024)

7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases by Region (2019-2024)

8.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2019-2024)

8.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

## **10 GLOBAL TARGETED DRUGS FOR NEURODEGENERATIVE DISEASES MARKET FORECAST**

10.1 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2025-2030)

10.1.1 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2025-2030)

10.1.2 Americas Targeted Drugs for Neurodegenerative Diseases Forecast

10.1.3 APAC Targeted Drugs for Neurodegenerative Diseases Forecast

10.1.4 Europe Targeted Drugs for Neurodegenerative Diseases Forecast

10.1.5 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Forecast

10.2 Americas Targeted Drugs for Neurodegenerative Diseases Forecast by Country (2025-2030)

10.2.1 United States Market Targeted Drugs for Neurodegenerative Diseases Forecast

10.2.2 Canada Market Targeted Drugs for Neurodegenerative Diseases Forecast

10.2.3 Mexico Market Targeted Drugs for Neurodegenerative Diseases Forecast

10.2.4 Brazil Market Targeted Drugs for Neurodegenerative Diseases Forecast

10.3 APAC Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2025-2030)

10.3.1 China Targeted Drugs for Neurodegenerative Diseases Market Forecast

10.3.2 Japan Market Targeted Drugs for Neurodegenerative Diseases Forecast

- 10.3.3 Korea Market Targeted Drugs for Neurodegenerative Diseases Forecast
- 10.3.4 Southeast Asia Market Targeted Drugs for Neurodegenerative Diseases Forecast
- 10.3.5 India Market Targeted Drugs for Neurodegenerative Diseases Forecast
- 10.3.6 Australia Market Targeted Drugs for Neurodegenerative Diseases Forecast
- 10.4 Europe Targeted Drugs for Neurodegenerative Diseases Forecast by Country (2025-2030)
  - 10.4.1 Germany Market Targeted Drugs for Neurodegenerative Diseases Forecast
  - 10.4.2 France Market Targeted Drugs for Neurodegenerative Diseases Forecast
  - 10.4.3 UK Market Targeted Drugs for Neurodegenerative Diseases Forecast
  - 10.4.4 Italy Market Targeted Drugs for Neurodegenerative Diseases Forecast
  - 10.4.5 Russia Market Targeted Drugs for Neurodegenerative Diseases Forecast
- 10.5 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Forecast by Region (2025-2030)
  - 10.5.1 Egypt Market Targeted Drugs for Neurodegenerative Diseases Forecast
  - 10.5.2 South Africa Market Targeted Drugs for Neurodegenerative Diseases Forecast
  - 10.5.3 Israel Market Targeted Drugs for Neurodegenerative Diseases Forecast
  - 10.5.4 Turkey Market Targeted Drugs for Neurodegenerative Diseases Forecast
- 10.6 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Type (2025-2030)
- 10.7 Global Targeted Drugs for Neurodegenerative Diseases Forecast by Application (2025-2030)
  - 10.7.1 GCC Countries Market Targeted Drugs for Neurodegenerative Diseases Forecast

## **11 KEY PLAYERS ANALYSIS**

- 11.1 Acadia Pharmaceuticals Inc.
  - 11.1.1 Acadia Pharmaceuticals Inc. Company Information
  - 11.1.2 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.1.4 Acadia Pharmaceuticals Inc. Main Business Overview
  - 11.1.5 Acadia Pharmaceuticals Inc. Latest Developments
- 11.2 Kyowa Kirin
  - 11.2.1 Kyowa Kirin Company Information
  - 11.2.2 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Revenue, Gross

## Margin and Market Share (2019-2024)

### 11.2.4 Kyowa Kirin Main Business Overview

### 11.2.5 Kyowa Kirin Latest Developments

## 11.3 Supernus Pharmaceuticals

### 11.3.1 Supernus Pharmaceuticals Company Information

### 11.3.2 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases

#### Product Offered

### 11.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases

#### Revenue, Gross Margin and Market Share (2019-2024)

### 11.3.4 Supernus Pharmaceuticals Main Business Overview

### 11.3.5 Supernus Pharmaceuticals Latest Developments

## 11.4 UCB

### 11.4.1 UCB Company Information

### 11.4.2 UCB Targeted Drugs for Neurodegenerative Diseases Product Offered

#### 11.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)

### 11.4.4 UCB Main Business Overview

### 11.4.5 UCB Latest Developments

## 11.5 Sumitomo Pharma

### 11.5.1 Sumitomo Pharma Company Information

#### 11.5.2 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Offered

#### 11.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)

### 11.5.4 Sumitomo Pharma Main Business Overview

### 11.5.5 Sumitomo Pharma Latest Developments

## 11.6 Biogen

### 11.6.1 Biogen Company Information

### 11.6.2 Biogen Targeted Drugs for Neurodegenerative Diseases Product Offered

#### 11.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)

### 11.6.4 Biogen Main Business Overview

### 11.6.5 Biogen Latest Developments

## 11.7 Eisai Inc.

### 11.7.1 Eisai Inc. Company Information

### 11.7.2 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered

#### 11.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)

### 11.7.4 Eisai Inc. Main Business Overview

- 11.7.5 Eisai Inc. Latest Developments
- 11.8 Eli Lilly
  - 11.8.1 Eli Lilly Company Information
  - 11.8.2 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.8.4 Eli Lilly Main Business Overview
  - 11.8.5 Eli Lilly Latest Developments
- 11.9 Green Valley
  - 11.9.1 Green Valley Company Information
  - 11.9.2 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.9.4 Green Valley Main Business Overview
  - 11.9.5 Green Valley Latest Developments
- 11.10 NOVARTIS
  - 11.10.1 NOVARTIS Company Information
  - 11.10.2 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.10.4 NOVARTIS Main Business Overview
  - 11.10.5 NOVARTIS Latest Developments
- 11.11 Bristol-Myers Squibb
  - 11.11.1 Bristol-Myers Squibb Company Information
  - 11.11.2 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.11.4 Bristol-Myers Squibb Main Business Overview
  - 11.11.5 Bristol-Myers Squibb Latest Developments
- 11.12 Janssen
  - 11.12.1 Janssen Company Information
  - 11.12.2 Janssen Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.12.4 Janssen Main Business Overview
  - 11.12.5 Janssen Latest Developments
- 11.13 Sanofi
  - 11.13.1 Sanofi Company Information

- 11.13.2 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Offered
- 11.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
- 11.13.4 Sanofi Main Business Overview
- 11.13.5 Sanofi Latest Developments
- 11.14 Roche
  - 11.14.1 Roche Company Information
  - 11.14.2 Roche Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.14.4 Roche Main Business Overview
  - 11.14.5 Roche Latest Developments
- 11.15 Neurocrine
  - 11.15.1 Neurocrine Company Information
  - 11.15.2 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.15.4 Neurocrine Main Business Overview
  - 11.15.5 Neurocrine Latest Developments
- 11.16 Lundbeck
  - 11.16.1 Lundbeck Company Information
  - 11.16.2 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.16.4 Lundbeck Main Business Overview
  - 11.16.5 Lundbeck Latest Developments
- 11.17 Teva
  - 11.17.1 Teva Company Information
  - 11.17.2 Teva Targeted Drugs for Neurodegenerative Diseases Product Offered
  - 11.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Revenue, Gross Margin and Market Share (2019-2024)
  - 11.17.4 Teva Main Business Overview
  - 11.17.5 Teva Latest Developments

## **12 RESEARCH FINDINGS AND CONCLUSION**

### **LIST OF TABLES**

.



Table 1.Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Region (2019 VS 2023 VS 2030) & (\$ millions)

Table 2.Targeted Drugs for Neurodegenerative Diseases Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Injection

Table 4. Major Players of Oral

Table 5.Targeted Drugs for Neurodegenerative Diseases Market Size CAGR byType (2019 VS 2023 VS 2030) & (\$ millions)

Table 6. GlobalTargeted Drugs for Neurodegenerative Diseases Market Size byType (2019-2024) & (\$ millions)

Table 7. GlobalTargeted Drugs for Neurodegenerative Diseases Market Size Market Share byType (2019-2024)

Table 8.Targeted Drugs for Neurodegenerative Diseases Market Size CAGR by Application (2019 VS 2023 VS 2030) & (\$ millions)

Table 9. GlobalTargeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024) & (\$ millions)

Table 10. GlobalTargeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2019-2024)

Table 11. GlobalTargeted Drugs for Neurodegenerative Diseases Revenue by Player (2019-2024) & (\$ millions)

Table 12. GlobalTargeted Drugs for Neurodegenerative Diseases Revenue Market Share by Player (2019-2024)

Table 13.Targeted Drugs for Neurodegenerative Diseases Key Players Head office and Products Offered

Table 14.Targeted Drugs for Neurodegenerative Diseases Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. GlobalTargeted Drugs for Neurodegenerative Diseases Market Size by Region (2019-2024) & (\$ millions)

Table 18. GlobalTargeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2019-2024)

Table 19. GlobalTargeted Drugs for Neurodegenerative Diseases Revenue by Country/Region (2019-2024) & (\$ millions)

Table 20. GlobalTargeted Drugs for Neurodegenerative Diseases Revenue Market Share by Country/Region (2019-2024)

Table 21. AmericasTargeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024) & (\$ millions)

Table 22. AmericasTargeted Drugs for Neurodegenerative Diseases Market Size



## Market Share by Country (2019-2024)

Table 23. AmericasTargeted Drugs for Neurodegenerative Diseases Market Size byType (2019-2024) & (\$ millions)

Table 24. AmericasTargeted Drugs for Neurodegenerative Diseases Market Size Market Share byType (2019-2024)

Table 25. AmericasTargeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024) & (\$ millions)

Table 26. AmericasTargeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2019-2024)

Table 27. APACTargeted Drugs for Neurodegenerative Diseases Market Size by Region (2019-2024) & (\$ millions)

Table 28. APACTargeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2019-2024)

Table 29. APACTargeted Drugs for Neurodegenerative Diseases Market Size byType (2019-2024) & (\$ millions)

Table 30. APACTargeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024) & (\$ millions)

Table 31. EuropeTargeted Drugs for Neurodegenerative Diseases Market Size by Country (2019-2024) & (\$ millions)

Table 32. EuropeTargeted Drugs for Neurodegenerative Diseases Market Size Market Share by Country (2019-2024)

Table 33. EuropeTargeted Drugs for Neurodegenerative Diseases Market Size byType (2019-2024) & (\$ millions)

Table 34. EuropeTargeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024) & (\$ millions)

Table 35. Middle East & AfricaTargeted Drugs for Neurodegenerative Diseases Market Size by Region (2019-2024) & (\$ millions)

Table 36. Middle East & AfricaTargeted Drugs for Neurodegenerative Diseases Market Size byType (2019-2024) & (\$ millions)

Table 37. Middle East & AfricaTargeted Drugs for Neurodegenerative Diseases Market Size by Application (2019-2024) & (\$ millions)

Table 38. Key Market Drivers & Growth Opportunities ofTargeted Drugs for Neurodegenerative Diseases

Table 39. Key Market Challenges & Risks ofTargeted Drugs for Neurodegenerative Diseases

Table 40. Key IndustryTrends ofTargeted Drugs for Neurodegenerative Diseases

Table 41. GlobalTargeted Drugs for Neurodegenerative Diseases Market SizeForecast by Region (2025-2030) & (\$ millions)

Table 42. GlobalTargeted Drugs for Neurodegenerative Diseases Market Size Market

## ShareForecast by Region (2025-2030)

Table 43. GlobalTargeted Drugs for Neurodegenerative Diseases Market SizeForecast byType (2025-2030) & (\$ millions)

Table 44. GlobalTargeted Drugs for Neurodegenerative Diseases Market SizeForecast by Application (2025-2030) & (\$ millions)

Table 45. Acadia Pharmaceuticals Inc. Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 46. Acadia Pharmaceuticals Inc.Targeted Drugs for Neurodegenerative Diseases Product Offered

Table 47. Acadia Pharmaceuticals Inc.Targeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 48. Acadia Pharmaceuticals Inc. Main Business

Table 49. Acadia Pharmaceuticals Inc. Latest Developments

Table 50. Kyowa Kirin Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 51. Kyowa KirinTargeted Drugs for Neurodegenerative Diseases Product Offered

Table 52. Kyowa KirinTargeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 53. Kyowa Kirin Main Business

Table 54. Kyowa Kirin Latest Developments

Table 55. Supernus Pharmaceuticals Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 56. Supernus PharmaceuticalsTargeted Drugs for Neurodegenerative Diseases Product Offered

Table 57. Supernus PharmaceuticalsTargeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 58. Supernus Pharmaceuticals Main Business

Table 59. Supernus Pharmaceuticals Latest Developments

Table 60. UCB Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 61. UCBTargeted Drugs for Neurodegenerative Diseases Product Offered

Table 62. UCBTargeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 63. UCB Main Business

Table 64. UCB Latest Developments

Table 65. Sumitomo Pharma Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 66. Sumitomo PharmaTargeted Drugs for Neurodegenerative Diseases Product Offered

Table 67. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 68. Sumitomo Pharma Main Business

Table 69. Sumitomo Pharma Latest Developments

Table 70. Biogen Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 71. Biogen Targeted Drugs for Neurodegenerative Diseases Product Offered

Table 72. Biogen Targeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 73. Biogen Main Business

Table 74. Biogen Latest Developments

Table 75. Eisai Inc. Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 76. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Offered

Table 77. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 78. Eisai Inc. Main Business

Table 79. Eisai Inc. Latest Developments

Table 80. Eli Lilly Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 81. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Offered

Table 82. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 83. Eli Lilly Main Business

Table 84. Eli Lilly Latest Developments

Table 85. Green Valley Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 86. Green Valley Targeted Drugs for Neurodegenerative Diseases Product Offered

Table 87. Green Valley Targeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 88. Green Valley Main Business

Table 89. Green Valley Latest Developments

Table 90. NOVARTIS Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 91. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Offered

Table 92. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 93. NOVARTIS Main Business

Table 94. NOVARTIS Latest Developments

Table 95. Bristol-Myers Squibb Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 96. Bristol-Myers SquibbTargeted Drugs for Neurodegenerative Diseases Product Offered

Table 97. Bristol-Myers SquibbTargeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 98. Bristol-Myers Squibb Main Business

Table 99. Bristol-Myers Squibb Latest Developments

Table 100. Janssen Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 101. JanssenTargeted Drugs for Neurodegenerative Diseases Product Offered

Table 102. JanssenTargeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 103. Janssen Main Business

Table 104. Janssen Latest Developments

Table 105. Sanofi Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 106. SanofiTargeted Drugs for Neurodegenerative Diseases Product Offered

Table 107. SanofiTargeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 108. Sanofi Main Business

Table 109. Sanofi Latest Developments

Table 110. Roche Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 111. RocheTargeted Drugs for Neurodegenerative Diseases Product Offered

Table 112. RocheTargeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 113. Roche Main Business

Table 114. Roche Latest Developments

Table 115. Neurocrine Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 116. NeurocrineTargeted Drugs for Neurodegenerative Diseases Product Offered

Table 117. NeurocrineTargeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 118. Neurocrine Main Business

Table 119. Neurocrine Latest Developments

Table 120. Lundbeck Details, CompanyType,Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 121. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Offered

Table 122. Lundbeck Targeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 123. Lundbeck Main Business

Table 124. Lundbeck Latest Developments

Table 125. Teva Details, Company Type, Targeted Drugs for Neurodegenerative Diseases Area Served and Its Competitors

Table 126. Teva Targeted Drugs for Neurodegenerative Diseases Product Offered

Table 127. Teva Targeted Drugs for Neurodegenerative Diseases Revenue (\$ million), Gross Margin and Market Share (2019-2024)

Table 128. Teva Main Business

Table 129. Teva Latest Developments

## LIST OFFIGURES

Figure 1. Targeted Drugs for Neurodegenerative Diseases Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate 2019-2030 (\$ millions)

Figure 6. Targeted Drugs for Neurodegenerative Diseases Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 7. Targeted Drugs for Neurodegenerative Diseases Sales Market Share by Country/Region (2023)

Figure 8. Targeted Drugs for Neurodegenerative Diseases Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 9. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type in 2023

Figure 10. Targeted Drugs for Neurodegenerative Diseases in Parkinson's Disease (PD)

Figure 11. Global Targeted Drugs for Neurodegenerative Diseases Market: Parkinson's Disease (PD) (2019-2024) & (\$ millions)

Figure 12. Targeted Drugs for Neurodegenerative Diseases in Alzheimer's Disease (AD)

Figure 13. Global Targeted Drugs for Neurodegenerative Diseases Market: Alzheimer's Disease (AD) (2019-2024) & (\$ millions)

Figure 14. Targeted Drugs for Neurodegenerative Diseases in Huntington's Disease (HD)



Figure 15. Global Targeted Drugs for Neurodegenerative Diseases Market: Huntington's Disease (HD) (2019-2024) & (\$ millions)

Figure 16. Targeted Drugs for Neurodegenerative Diseases in Tardive Dyskinesia (TD)

Figure 17. Global Targeted Drugs for Neurodegenerative Diseases Market: Tardive Dyskinesia (TD) (2019-2024) & (\$ millions)

Figure 18. Targeted Drugs for Neurodegenerative Diseases in Multiple Sclerosis (MS)

Figure 19. Global Targeted Drugs for Neurodegenerative Diseases Market: Multiple Sclerosis (MS) (2019-2024) & (\$ millions)

Figure 20. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application in 2023

Figure 21. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Player in 2023

Figure 22. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2019-2024)

Figure 23. Americas Targeted Drugs for Neurodegenerative Diseases Market Size 2019-2024 (\$ millions)

Figure 24. APAC Targeted Drugs for Neurodegenerative Diseases Market Size 2019-2024 (\$ millions)

Figure 25. Europe Targeted Drugs for Neurodegenerative Diseases Market Size 2019-2024 (\$ millions)

Figure 26. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size 2019-2024 (\$ millions)

Figure 27. Americas Targeted Drugs for Neurodegenerative Diseases Value Market Share by Country in 2023

Figure 28. United States Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 29. Canada Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 30. Mexico Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 31. Brazil Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 32. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region in 2023

Figure 33. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2019-2024)

Figure 34. APAC Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2019-2024)

Figure 35. China Targeted Drugs for Neurodegenerative Diseases Market Size Growth

2019-2024 (\$ millions)

Figure 36. Japan Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 37. South Korea Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 38. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 39. India Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 40. Australia Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 41. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Country in 2023

Figure 42. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2019-2024)

Figure 43. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2019-2024)

Figure 44. Germany Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 45. France Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 46. UK Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 47. Italy Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 48. Russia Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 49. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region (2019-2024)

Figure 50. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2019-2024)

Figure 51. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Application (2019-2024)

Figure 52. Egypt Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 53. South Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 54. Israel Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 55. Turkey Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 56. GCC Countries Targeted Drugs for Neurodegenerative Diseases Market Size Growth 2019-2024 (\$ millions)

Figure 57. Americas Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 58. APAC Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 59. Europe Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 60. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 61. United States Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 62. Canada Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 63. Mexico Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 64. Brazil Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 65. China Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 66. Japan Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 67. Korea Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 68. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 69. India Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 70. Australia Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 71. Germany Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 72. France Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 73. UK Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 74. Italy Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030



(\$ millions)

Figure 75. Russia Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 76. Egypt Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 77. South Africa Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 78. Israel Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 79. Turkey Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 80. GCC Countries Targeted Drugs for Neurodegenerative Diseases Market Size 2025-2030 (\$ millions)

Figure 81. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share Forecast by Type (2025-2030)

Figure 82. Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share Forecast by Application (2025-2030)

## I would like to order

Product name: Global Targeted Drugs for Neurodegenerative Diseases Market Growth (Status and Outlook) 2024-2030

Product link: <https://marketpublishers.com/r/G88F05573551EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G88F05573551EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

